Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03834662 · ClinicalTrials.gov registry record · Phase 1
A Trial of AVID200, a Transforming Growth Factor β (TGFβ) Inhibitor, in Patients Malignancies
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT03834662 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 19 participants.
The verdict
NCT03834662, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
TGFβ has profound local immunosuppressive and immunoexclusion effects in the tumor microenvironment that are integrally involved in the failure of immune checkpoint inhibitors in some tumors. Preclinical data in a variety of models strongly support the study of AVID200 in patients with treatment-refractory advanced and metastatic malignancies as an approach to reducing immunosuppression/exclusion and increasing the activity of immune checkpoint inhibitors.
Interventions
- DRUG AVID200
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2019-01-07 |
| Est. Completion | 2020-02-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03834662
The ClinicalTrials.gov registry entry for NCT03834662 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AVID200 is the first listed.
NCT03834662 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03834662 about?
NCT03834662 is a clinical study titled "A Trial of AVID200, a Transforming Growth Factor β (TGFβ) Inhibitor, in Patients Malignancies". TGFβ has profound local immunosuppressive and immunoexclusion effects in the tumor microenvironment that are integrally involved in the failure of immune checkpoint inhibitors in some tumors. Preclinical data in a variety of models strongly support the study of AVID200 in patients with treatment-ref...
What is the current status of trial NCT03834662?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2019-01-07. Estimated completion is 2020-02-19.
What interventions are being tested in trial NCT03834662?
The interventions under investigation include: AVID200 (DRUG).
Who is sponsoring clinical trial NCT03834662?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.